Pharmaceutical Industry in China to 2020: An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges
“Pharmaceutical Industry in China to 2020: An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challengess” provides a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 265 tables & figures within 182 pages. The Chinese biopharmaceutical market is presented as follows:
What you will gain:
- By Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN, SHANGHAI HUAGUAN BIOCHIP, SIBIONO GENETECH, ABBOTT, ROCHE, PFIZER, GSK, NOVARTIS)
- By Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)
- Company financials, sales & revenue figures
- China GDP, economic growth, export (bulk drug, formulations) figures
- Indian health expenditure as a function of GDP
- Growth change figures of emerging and developing countries (India, Russia, China, Brazil)
- Economic growth figures of advanced economies (USA, UK, Germany, France, Italy, Spain, Japan, Canada)
- Projected figures of strategic emerging industry GDP percentage contribution
- Key strengths, weaknesses and threats influencing leading player position within the market
- Top Five Contract Pharmaceutical Export Markets of China
- Major players within China’s leading therapeutic markets (e.g., cancer, allergy, liver disease)
- Multinational penetration into the Chinese Pharma Market
- Comprehensive product portfolios, R&D activity and pipeline therapeutics
- M&A activity and future strategies of top Chinese pharmacos
- Economic indicators, trade policy, merchandise and commercial trade statistics
- Gross Domestic Product of China, historic and projection analysis
- Chinese economic outlook in comparison to advanced economies
- Three Tier ‘Pharmerging’ Markets with Potential for Significant Growth
- Prescription drug sales distribution channels in China
- Major biogeneric products in China
- Amoytop Biotech
- Active Pharmaceutical Products
- Beijing Continent Pharmaceuticals
- FusoGen Pharmaceuticals
- Shanghai Huaguan Biochip
- SiBiono GeneTech
- Abbott
- AstraZeneca
- Boehringer Ingelheim
- Eli Lilly
- GlaxoSmithKline
- Johnson & Johnson Medical
- Merck
- Novartis
- Pfizer
- Roche
What you will gain:
- An in-depth understanding of the Chinese biopharmaceutical market and it’s environment
- Current market facts, figures and product lines of key players in the industry
- An insight into how generic therapeutics will propagate the Chinese biopharmaceutical market
- Knowledge of how the Chinese pharma market will integrate into the global healthcare market
- Information on key regulatory and government policies
- Data on levels of private and publically funded biopharma studies in China
- Strategies on how to adapt and restructure current business models to this industry
- Lack of regulatory policy and legislation
- Reimbursement schemes and payers concerns
- Funding and government sponsorship issues
- International scepticism of Chinese safety and efficacy therapeutic profiles
- Strong, competitive players
- Pooling their resources for specific growth and therapeutic areas
- Investing strategically in R&D
- Have a history of strategic M&A activity
1. SUMMARY
1.1. Objectives of Report
1.2. Scope of Study
1.3. Data Sources and Methodology
1.4. Key Findings and Observations
1.5. Executive Summary
1.5.1. Chronic Disease in China
1.5.2. Chinese Pharmaceutical Market
1.5.3. Government and Regulation Environment 12th Five Year Plan
1.5.4. Generic Medication Market and China
1.5.5. Novel Product Drug development
1.5.6. Global Pharmaceutical Companies Interest in China
2. CHRONIC DISEASE PREVALENCE STATISTICS
3. BUSINESS ENVIRONMENT
3.1. Economic Indicators, Trade Policy and Merchandise and Commercial Trade Statistics
3.2. Gross Domestic Product of China Analysis
3.3. Annual Health Expenditure in China Analysis
3.4. Global and Chinese Economic History
3.5. Chinese Economic History in Comparison to Emerging Markets and Developing Countries
3.6. Chinese Economic History in Comparison to Advanced Economies (US, Europe)
4. CHINESE PHARMACEUTICAL MARKET
4.1. Global Pharma Market Overview
4.2. China Pharma Market Overview
4.3. Main Players in China’s Pharmaceutical Industry
4.3.1. Anti-Allergy Drug Market
4.3.2. Asthma/COPD Drug Market
4.3.3. Benign Prostate Hyperplasia Drug Market
4.3.4. Anti-Depressant Drug market
4.3.5. Dermatitis Drug Market
4.3.6. Diabetes Drug Market
4.3.7. Hypertension Drug Market
4.3.8. Dyslipidaemia Drug Market
4.3.9. Senile Dementia Drug Market
4.3.10. Cancer Drug Market
4.3.11. Rheumatoid Arthritis Drug Market
4.3.12. Ophthalmological Drug Market
4.3.13. Liver Disease Drug Market
4.3.14. Antibiotic Drug Market
4.3.15. Vaccine Market
5. GOVERNMENT AND REGULATION ENVIRONMENT
5.1. 12th Five Year Plan
5.2. Intellectual Property for Pharmaceuticals in China
5.3. State Food and Drug Administration (SFDA)
5.4. Pharmaceutical Distribution Process in China
5.5. Multinational Company Strategy for the Essential Drug List
5.5.1. Expanded Coverage of Medical Conditions
5.5.2. A Standardized Essential Drug List
5.5.3. Increased EDL Use in Class 3 and Class 2 Hospitals
5.5.4. Increased Product Quality
5.6. How did Zocor Gain Access to the National Essential Drug List?
5.7. What are the Top Selling Agents from Multinational Companies on the Essential Drug List?
5.8. What Key Strategies Should be Investigated Prior to Essential Drug List Integration?
6. CHINA – SECOND LARGEST PHARMA MARKET 2014
6.1. China – At the Forefront of Emerging Markets
6.2. Generic Medication Market and China
6.3. Novel Product Drug Development
6.4. Drug Development Cost and Outsourcing
6.5. Drug Development Case Study - Beijing Continent Pharmaceuticals
6.6. China’s Pharmaceutical Export Market
6.7. Spot Light - China Medical City Taizhou
7. GLOBAL PHARMACEUTICAL COMPANIES INTEREST IN CHINA
7.1. Abbott
7.1.1. AbbVie China
7.2. AstraZeneca China
7.3. Bayer China
7.4. Boehringer Ingelheim China
7.5. Eli Lilly China
7.6. GlaxoSmithKline China
7.7. Johnson & Johnson Medical China
7.8. Merck China
7.9. Novartis China
7.10. Novo Nordisk China
7.11. Pfizer China
7.11.1. Pfizer China R&D Centre
7.11.2. Pfizer China Products
7.11.3. Pfizer Financials
7.12. Roche China
янв.03 Sanofi China
8. CHINESE PHARMACEUTICAL COMPANIES
8.1. Amoytop Biotech
8.1.1. Overview
8.1.2. Active Pharmaceutical Products
8.2.1. Research and Development
8.2.2. Financial Information
8.3. Beijing Continent Pharmaceuticals
8.4. FusoGen Pharmaceuticals
8.4.1. Financial Information
8.5. Shanghai Huaguan Biochip
8.5.1. Financial Information
8.6. SiBiono GeneTech
8.6.1. Financial Information
8.7. Sinovac Biotech
8.7.1. Financial Information
8.7.2. New Products
8.7.3. Split Virion Pandemic Influenza Vaccine
8.7.4. RabEnd
8.7.5. Pipeline Portfolio
8.7.6. EV71 virus Vaccine
8.7.7. Pneumococcal Conjugate Vaccine
8.7.8. Pneumococcal Polysaccharide Vaccine
8.7.9. Varicella Vaccine
8.7.10. Measles, Mumps and Rubella Vaccines
8.7.11. Rotavirus Vaccine
9. DRIVERS, RESTRAINTS, CHALLENGES AND OPPORTUNITY ANALYSIS
9.1. Key Drivers of the Pharmaceutical Market in China
9.2. Key Restraints of the Pharmaceutical Market in China
9.3. Challenges of the Pharmaceutical Industry in China
9.4. Opportunities Within BioPharma China
1.1. Objectives of Report
1.2. Scope of Study
1.3. Data Sources and Methodology
1.4. Key Findings and Observations
1.5. Executive Summary
1.5.1. Chronic Disease in China
1.5.2. Chinese Pharmaceutical Market
1.5.3. Government and Regulation Environment 12th Five Year Plan
1.5.4. Generic Medication Market and China
1.5.5. Novel Product Drug development
1.5.6. Global Pharmaceutical Companies Interest in China
2. CHRONIC DISEASE PREVALENCE STATISTICS
3. BUSINESS ENVIRONMENT
3.1. Economic Indicators, Trade Policy and Merchandise and Commercial Trade Statistics
3.2. Gross Domestic Product of China Analysis
3.3. Annual Health Expenditure in China Analysis
3.4. Global and Chinese Economic History
3.5. Chinese Economic History in Comparison to Emerging Markets and Developing Countries
3.6. Chinese Economic History in Comparison to Advanced Economies (US, Europe)
4. CHINESE PHARMACEUTICAL MARKET
4.1. Global Pharma Market Overview
4.2. China Pharma Market Overview
4.3. Main Players in China’s Pharmaceutical Industry
4.3.1. Anti-Allergy Drug Market
4.3.2. Asthma/COPD Drug Market
4.3.3. Benign Prostate Hyperplasia Drug Market
4.3.4. Anti-Depressant Drug market
4.3.5. Dermatitis Drug Market
4.3.6. Diabetes Drug Market
4.3.7. Hypertension Drug Market
4.3.8. Dyslipidaemia Drug Market
4.3.9. Senile Dementia Drug Market
4.3.10. Cancer Drug Market
4.3.11. Rheumatoid Arthritis Drug Market
4.3.12. Ophthalmological Drug Market
4.3.13. Liver Disease Drug Market
4.3.14. Antibiotic Drug Market
4.3.15. Vaccine Market
5. GOVERNMENT AND REGULATION ENVIRONMENT
5.1. 12th Five Year Plan
5.2. Intellectual Property for Pharmaceuticals in China
5.3. State Food and Drug Administration (SFDA)
5.4. Pharmaceutical Distribution Process in China
5.5. Multinational Company Strategy for the Essential Drug List
5.5.1. Expanded Coverage of Medical Conditions
5.5.2. A Standardized Essential Drug List
5.5.3. Increased EDL Use in Class 3 and Class 2 Hospitals
5.5.4. Increased Product Quality
5.6. How did Zocor Gain Access to the National Essential Drug List?
5.7. What are the Top Selling Agents from Multinational Companies on the Essential Drug List?
5.8. What Key Strategies Should be Investigated Prior to Essential Drug List Integration?
6. CHINA – SECOND LARGEST PHARMA MARKET 2014
6.1. China – At the Forefront of Emerging Markets
6.2. Generic Medication Market and China
6.3. Novel Product Drug Development
6.4. Drug Development Cost and Outsourcing
6.5. Drug Development Case Study - Beijing Continent Pharmaceuticals
6.6. China’s Pharmaceutical Export Market
6.7. Spot Light - China Medical City Taizhou
7. GLOBAL PHARMACEUTICAL COMPANIES INTEREST IN CHINA
7.1. Abbott
7.1.1. AbbVie China
7.2. AstraZeneca China
7.3. Bayer China
7.4. Boehringer Ingelheim China
7.5. Eli Lilly China
7.6. GlaxoSmithKline China
7.7. Johnson & Johnson Medical China
7.8. Merck China
7.9. Novartis China
7.10. Novo Nordisk China
7.11. Pfizer China
7.11.1. Pfizer China R&D Centre
7.11.2. Pfizer China Products
7.11.3. Pfizer Financials
7.12. Roche China
янв.03 Sanofi China
8. CHINESE PHARMACEUTICAL COMPANIES
8.1. Amoytop Biotech
8.1.1. Overview
8.1.2. Active Pharmaceutical Products
8.2.1. Research and Development
8.2.2. Financial Information
8.3. Beijing Continent Pharmaceuticals
8.4. FusoGen Pharmaceuticals
8.4.1. Financial Information
8.5. Shanghai Huaguan Biochip
8.5.1. Financial Information
8.6. SiBiono GeneTech
8.6.1. Financial Information
8.7. Sinovac Biotech
8.7.1. Financial Information
8.7.2. New Products
8.7.3. Split Virion Pandemic Influenza Vaccine
8.7.4. RabEnd
8.7.5. Pipeline Portfolio
8.7.6. EV71 virus Vaccine
8.7.7. Pneumococcal Conjugate Vaccine
8.7.8. Pneumococcal Polysaccharide Vaccine
8.7.9. Varicella Vaccine
8.7.10. Measles, Mumps and Rubella Vaccines
8.7.11. Rotavirus Vaccine
9. DRIVERS, RESTRAINTS, CHALLENGES AND OPPORTUNITY ANALYSIS
9.1. Key Drivers of the Pharmaceutical Market in China
9.2. Key Restraints of the Pharmaceutical Market in China
9.3. Challenges of the Pharmaceutical Industry in China
9.4. Opportunities Within BioPharma China
LIST OF TABLES
Table 2.1: Most Prominent Cancer Manifestations in China
Table 2.2: Top Fifty Diseases in China Today (non-cancer)
Table 2.3: Top Infectious Disease States in China Today
Table 3.1: World Trade Organisation Basic Indicators on China
Table 3.2: World Trade Organisation Trade Policy of China
Table 3.3: World Trade Organisation Merchandise Trade Statistics: China
Table 3.4: World Trade Organisation Commercial Services Trade Statistics: China
Table 3.5: Summary of International Monetary Fund Members’ Quota, Reserve Position, SDR Holdings, Outstanding Credit, Recent Lending Arrangements, Projected Payments Due and Monthly Historical Transactions of China
Table 3.6: China Statistics
Table 4.1: Top Global Pharma Markets 2003-2013
Table 4.2: Major Players in China’s Anti-Allergy Drug Market
Table 4.3: Major Players in China’s Asthma Drug Market
Table 4.4: Major Players in China’s Benign Prostate Hyperplasia (BPH) Drug Market
Table 4.5: Major Players in China’s Anti-Depressant Drug Market
Table 4.6: Prescription Dermatitis Drug Industry Sub-Markets and Associated Therapeutics
Table 4.7: Top Prescription Dermatitis Drugs on the Chinese Market
Table 4.8: Major Players in China’s Dermatitis Drug Market
Table 4.9: Major Players in China’s Diabetic Drug Market
Table 4.10: Major Players in China’s Hypertension Drug Market
Table 4.11: Major Players in China’s Dyslipidaemia Drug Market
Table 4.12: Major Players in China’s Senile Dementia Drug Market
Table 4.13: Major Players in China’s Cancer Drug Market
Table 4.14: Major Players in China’s Rheumatoid Arthritis Drug Market
Table 4.15: Major Players in China’s Ophthalmological Drug Market
Table 4.16: Major Players in China’s Liver Disease Drug Market
Table 4.17: Major Players in China’s Antibiotic Drug Market
Table 5.1: Seven Strategic Emerging Industries of China’s 12th Five Year Plan 2011-2015
Table 5.2: Outline of the Chinese Promotion Plan for the Implementation of the National Intellectual Property Strategy, 2012
Table 5.3: Challenges facing the Pharmaceutical Distribution Business in China
Table 5.4: Prescription Drug Sales Distribution Channels in China
Table 5.5: Extra Government Guidelines for the Chinese Essential Drug System
Table 6.1: Major Biogeneric Products in China
Table 6.2: Imported Therapeutics with Administrative Protection in China
Table 6.3: Expired Proprietary Pharmaceuticals in China
Table 6.4: Reasons Why Multinational Companies Seek CMO’s in China
Table 6.5: Comparison of Clinical Trial Cost between China and the USA
Table 6.6: Five Functional Districts of China Medical City
Table 6.7: Five Key R&D and Manufacturing Areas within China Medical City
Table 7.1: Top Multinational Company Performance, China
Table 7.2: Abbott Areas of Expertise
Table 7.3: Abbott Key Global Products
Table 7.4: AbbVie (Abbott) Speciality Care Products Holding Market-Leading Positions
Table 7.5: Abbott China Anaesthesia Product Profile
Table 7.6: Abbott China Cardiovascular Product Profile
Table 7.7: Abbott China Vaccine Product Profile
Table 7.8: Abbott China Digestion Product Profile
Table 7.9: Abbott China HIV Product Profile
Table 7.10: Abbott Rheumatology HIV Product Profile
Table 7.11 Abbott China Gynaecological Product Profile
Table 7.12 Abbott China Urological Product Profile
Table 7.13 Abbott China Liver Disease Product Profile
Table 7.14 Abbott China Diagnostic Product Profile
Table 7.15: Abbott China Molecular Diagnostic Product Profile
Table 7.16: Abbott Blood Glucose Meter Product Profile
Table 7.17: Abbott Cardiovascular Product Profile
Table 7.18: Abbott Rapid Bedside Diagnostic/ Point of Care Product Profile
Table 7.19: Important Milestones in AstraZeneca China’s History
Table 7.20: AstraZeneca China Anaesthetic Range of Products
Table 7.21: AstraZeneca China Cardiovascular and Metabolism Range of Products
Table 7.22: AstraZeneca China Gastrointestinal Range of Products
Table 7.23: AstraZeneca China Infection Range of Products
Table 7.24: AstraZeneca China Neurology Range of Products
Table 7.25: AstraZeneca China Oncology Range of Products
Table 7.26: AstraZeneca China Respiratory Range of Products
Table 7.27: AstraZeneca Top Branded Pharmaceuticals Globally
Table 7.28: AstraZeneca Sales (US$ Mil) of Top Branded Pharmaceuticals Globally
Table 7.29: Bayer China Important Milestones
Table 7.30: Therapeutic Areas Covered by Bayer Healthcare Pharmaceuticals in China
Table 7.31: Bayer - Leading Therapeutics in China
Table 7.32: Bayer Top Selling Consumer Health Products
Table 7.33: Bayer Key Product Patent Expiration Dates China
Table 7.34: Boehringer Ingelheim Major Products in China
Table 7.35: Main Therapeutic Areas of Interest to Boehringer Ingelheim China
Table 7.36: Global Therapeutic Pipeline, Boehringer Ingelheim
Table 7.37: Major Global Boehringer Ingelheim Therapeutic Products
Table 7.38: Lilly Late Stage New Molecular Entities: Indication, Geography & Developments
Table 7.39: Lilly New Molecular Entities Approved, Under Regulatory Review & in Clinical Trials in the US, Japan and Europe
Table 7.40: Lilly Key Product by US Revenue and Patent Protection Data FY2014
Table 7.41: Lilly Key Product by Non-US Revenue and Patent Protection Data FY2014
Table 7.42: Eli Lilly Top Selling Global Branded Pharmaceuticals 2012-2013 & Percentage Change
Table 7.43: Lilly Top Selling Global Branded Pharmaceuticals FY2014 ($ millions) Within and Outside the US Market
Table 7.44: GlaxoSmithKline Prescription Portfolio and Indications in China
Table 7.45: GlaxoSmithKline Vaccine Portfolio and Indications in China
Table 7.46: GlaxoSmithKline Over the Counter Portfolio and Indications in China
Table 7.47: GlaxoSmithKline Global Pharmaceutical Sales by Therapeutic Area, FY2012-2014
Table 7.48: GlaxoSmithKline Global Vaccine Sales FY2012-2013
Table 7.49: Significant Milestones in Johnson and Johnson China History
Table 7.50: Johnson & Johnson Pharmaceutical Segment Sales (US$ Billion) by Therapeutic Area and Percentage Change, 2012-2014
Table 7.51: Merck Serono Pharmaceutical Key Therapeutic Areas in China
Table 7.52: Merck Serono Fertility and Infertility Therapeutic Portfolio in China
Table 7.53: Merck Serono Therapeutic Portfolio in China
Table 7.54: Merck Pharmaceutical Hong Kong Therapeutic Portfolio
Table 7.55: Merck Main Pharmaceutical Brand Sales Figures FY2012-FY2014
Table 7.56: Merck Global Pharmaceutical, Animal Health and Consumer Health Sales 2012-2013
Table 7.57: Merck Top Ten Global Pharmaceutical Brand Sales 2012-2013
Table 7.58: Range of Diabetic Products from Novo Nordisk China
Table 7.59: QUICKFACTs - Pfizer China
Table 7.60: Important Milestones – Pfizer China
Table 7.61: Pfizer Range of Infectious Disease Therapeutics for Chinese Health Care Market
Table 7.62: Pfizer Range of Mental Health Products for Chinese Health Care Market
Table 7.63: Pfizer Range of Genitourinary Products for Chinese Health Care Market
Table 7.64: Pfizer Range of Endocrine Products for Chinese Health Care Market
Table 7.65: Pfizer Range of Women’s Health Products for Chinese Health Care Market
Table 7.66: Pfizer Range of Cardiovascular Disease Products for Chinese Health Care Market
Table 7.67: Pfizer China – Range of Oncology Products for Chinese Health Care Market
Table 7.68: Pfizer Key Consumer Healthcare Global Products
Table 7.69: Pfizer Key Speciality Care Global Products
Table 7.70: Pfizer Key Oncology Global Products
Table 7.71: Pfizer Key Global Established Products
Table 7.72: Pfizer Key Innovative Products in Emerging Markets
Table 7.73: Pfizer Key Animal Health Global Products
Table 7.74: Pfizer Product Sales with Significant Impact on Revenues 2013:2014 Comparison
Table 7.75: Roche Pharmaceuticals Product List in China
Table 7.76: Roche Global Sales (CHF Millions) by Therapeutic Area, 2012-2014 and Percentage Change (CER)
Table 7.77: Roche Pharmaceutical Division Sales from Brazil, China, India, Mexico, Russia, South Korea, Turkey, 2011-2014 and Percentage Change (CER)
Table 7.78: Seven Growth Platforms of Sanofi China
Table 7.79: Key Therapeutic Areas of Sanofi China
Table 8.1: Important Milestones in Amoytop Biotech’s Development
Table 8.2: Amoytop Biotech Main Objectives of Research and Development Division
Table 8.3: Amoytop Biotech Panel of Recombinant Protein Therapeutics in Clinical Studies
Table 8.4: Amoytop Biotech Portfolio of Patented Y-Shaped Branched Pegylated Recombinant Protein Therapeutics within Clinical Investigation in China
Table 8.5: Current Recombinant protein therapeutics by Amoytop Biotech
Table 8.6: Active Pharmaceutical Product Portfolio of Amoytop Biotech
Table 8.7: Milestones Achieved by FusoGen Pharmaceuticals
Table 8.8: Research and Development Sub-groups of FusoGen Pharmaceuticals
Table 8.9: Shanghai Huaguan Biochip Rapid Test Portfolio
Table 8.10: Shanghai Huaguan Biochip Multi Drugs of Abuse Test Profile
Table 8.11: Shanghai Huaguan Biochip Infectious Disease Test Portfolio
Table 8.12: Shanghai Huaguan Biochip Diagnostic Test Portfolio
Table 8.13: Shanghai Huaguan Biochip Laboratory Service Portfolio
Table 8.14: Intracellular Functions of the Gene Therapy Agent, Gendicine by SiBiono GeneTech
Table 8.15: Gendicine - Potential Oncology Indications for Future Approval
Table 8.16: Current Human Vaccine Portfolio of Sinovac Biotech
Table 8.17: Important Milestones in the History of Sinovac Biotech
Table 8.18: Pipeline Portfolio of Sinovac Biotech
Table 8.19: Total Sales Figures Sinovac Biotech 2007-2012
Table 9.1: Key Drivers of the Pharmaceutical Market in China
Table 9.2: Key Restraints of the Pharmaceutical Market in China
Table 9.3: Key Challenges of the Pharmaceutical Market in China
Table 9.4: Patent Expirations of Selected Top Brand Name Therapeutics by 2020
Table 9.5: Leading Pharmaceutical Areas with Significant Opportunities in China
Table 2.1: Most Prominent Cancer Manifestations in China
Table 2.2: Top Fifty Diseases in China Today (non-cancer)
Table 2.3: Top Infectious Disease States in China Today
Table 3.1: World Trade Organisation Basic Indicators on China
Table 3.2: World Trade Organisation Trade Policy of China
Table 3.3: World Trade Organisation Merchandise Trade Statistics: China
Table 3.4: World Trade Organisation Commercial Services Trade Statistics: China
Table 3.5: Summary of International Monetary Fund Members’ Quota, Reserve Position, SDR Holdings, Outstanding Credit, Recent Lending Arrangements, Projected Payments Due and Monthly Historical Transactions of China
Table 3.6: China Statistics
Table 4.1: Top Global Pharma Markets 2003-2013
Table 4.2: Major Players in China’s Anti-Allergy Drug Market
Table 4.3: Major Players in China’s Asthma Drug Market
Table 4.4: Major Players in China’s Benign Prostate Hyperplasia (BPH) Drug Market
Table 4.5: Major Players in China’s Anti-Depressant Drug Market
Table 4.6: Prescription Dermatitis Drug Industry Sub-Markets and Associated Therapeutics
Table 4.7: Top Prescription Dermatitis Drugs on the Chinese Market
Table 4.8: Major Players in China’s Dermatitis Drug Market
Table 4.9: Major Players in China’s Diabetic Drug Market
Table 4.10: Major Players in China’s Hypertension Drug Market
Table 4.11: Major Players in China’s Dyslipidaemia Drug Market
Table 4.12: Major Players in China’s Senile Dementia Drug Market
Table 4.13: Major Players in China’s Cancer Drug Market
Table 4.14: Major Players in China’s Rheumatoid Arthritis Drug Market
Table 4.15: Major Players in China’s Ophthalmological Drug Market
Table 4.16: Major Players in China’s Liver Disease Drug Market
Table 4.17: Major Players in China’s Antibiotic Drug Market
Table 5.1: Seven Strategic Emerging Industries of China’s 12th Five Year Plan 2011-2015
Table 5.2: Outline of the Chinese Promotion Plan for the Implementation of the National Intellectual Property Strategy, 2012
Table 5.3: Challenges facing the Pharmaceutical Distribution Business in China
Table 5.4: Prescription Drug Sales Distribution Channels in China
Table 5.5: Extra Government Guidelines for the Chinese Essential Drug System
Table 6.1: Major Biogeneric Products in China
Table 6.2: Imported Therapeutics with Administrative Protection in China
Table 6.3: Expired Proprietary Pharmaceuticals in China
Table 6.4: Reasons Why Multinational Companies Seek CMO’s in China
Table 6.5: Comparison of Clinical Trial Cost between China and the USA
Table 6.6: Five Functional Districts of China Medical City
Table 6.7: Five Key R&D and Manufacturing Areas within China Medical City
Table 7.1: Top Multinational Company Performance, China
Table 7.2: Abbott Areas of Expertise
Table 7.3: Abbott Key Global Products
Table 7.4: AbbVie (Abbott) Speciality Care Products Holding Market-Leading Positions
Table 7.5: Abbott China Anaesthesia Product Profile
Table 7.6: Abbott China Cardiovascular Product Profile
Table 7.7: Abbott China Vaccine Product Profile
Table 7.8: Abbott China Digestion Product Profile
Table 7.9: Abbott China HIV Product Profile
Table 7.10: Abbott Rheumatology HIV Product Profile
Table 7.11 Abbott China Gynaecological Product Profile
Table 7.12 Abbott China Urological Product Profile
Table 7.13 Abbott China Liver Disease Product Profile
Table 7.14 Abbott China Diagnostic Product Profile
Table 7.15: Abbott China Molecular Diagnostic Product Profile
Table 7.16: Abbott Blood Glucose Meter Product Profile
Table 7.17: Abbott Cardiovascular Product Profile
Table 7.18: Abbott Rapid Bedside Diagnostic/ Point of Care Product Profile
Table 7.19: Important Milestones in AstraZeneca China’s History
Table 7.20: AstraZeneca China Anaesthetic Range of Products
Table 7.21: AstraZeneca China Cardiovascular and Metabolism Range of Products
Table 7.22: AstraZeneca China Gastrointestinal Range of Products
Table 7.23: AstraZeneca China Infection Range of Products
Table 7.24: AstraZeneca China Neurology Range of Products
Table 7.25: AstraZeneca China Oncology Range of Products
Table 7.26: AstraZeneca China Respiratory Range of Products
Table 7.27: AstraZeneca Top Branded Pharmaceuticals Globally
Table 7.28: AstraZeneca Sales (US$ Mil) of Top Branded Pharmaceuticals Globally
Table 7.29: Bayer China Important Milestones
Table 7.30: Therapeutic Areas Covered by Bayer Healthcare Pharmaceuticals in China
Table 7.31: Bayer - Leading Therapeutics in China
Table 7.32: Bayer Top Selling Consumer Health Products
Table 7.33: Bayer Key Product Patent Expiration Dates China
Table 7.34: Boehringer Ingelheim Major Products in China
Table 7.35: Main Therapeutic Areas of Interest to Boehringer Ingelheim China
Table 7.36: Global Therapeutic Pipeline, Boehringer Ingelheim
Table 7.37: Major Global Boehringer Ingelheim Therapeutic Products
Table 7.38: Lilly Late Stage New Molecular Entities: Indication, Geography & Developments
Table 7.39: Lilly New Molecular Entities Approved, Under Regulatory Review & in Clinical Trials in the US, Japan and Europe
Table 7.40: Lilly Key Product by US Revenue and Patent Protection Data FY2014
Table 7.41: Lilly Key Product by Non-US Revenue and Patent Protection Data FY2014
Table 7.42: Eli Lilly Top Selling Global Branded Pharmaceuticals 2012-2013 & Percentage Change
Table 7.43: Lilly Top Selling Global Branded Pharmaceuticals FY2014 ($ millions) Within and Outside the US Market
Table 7.44: GlaxoSmithKline Prescription Portfolio and Indications in China
Table 7.45: GlaxoSmithKline Vaccine Portfolio and Indications in China
Table 7.46: GlaxoSmithKline Over the Counter Portfolio and Indications in China
Table 7.47: GlaxoSmithKline Global Pharmaceutical Sales by Therapeutic Area, FY2012-2014
Table 7.48: GlaxoSmithKline Global Vaccine Sales FY2012-2013
Table 7.49: Significant Milestones in Johnson and Johnson China History
Table 7.50: Johnson & Johnson Pharmaceutical Segment Sales (US$ Billion) by Therapeutic Area and Percentage Change, 2012-2014
Table 7.51: Merck Serono Pharmaceutical Key Therapeutic Areas in China
Table 7.52: Merck Serono Fertility and Infertility Therapeutic Portfolio in China
Table 7.53: Merck Serono Therapeutic Portfolio in China
Table 7.54: Merck Pharmaceutical Hong Kong Therapeutic Portfolio
Table 7.55: Merck Main Pharmaceutical Brand Sales Figures FY2012-FY2014
Table 7.56: Merck Global Pharmaceutical, Animal Health and Consumer Health Sales 2012-2013
Table 7.57: Merck Top Ten Global Pharmaceutical Brand Sales 2012-2013
Table 7.58: Range of Diabetic Products from Novo Nordisk China
Table 7.59: QUICKFACTs - Pfizer China
Table 7.60: Important Milestones – Pfizer China
Table 7.61: Pfizer Range of Infectious Disease Therapeutics for Chinese Health Care Market
Table 7.62: Pfizer Range of Mental Health Products for Chinese Health Care Market
Table 7.63: Pfizer Range of Genitourinary Products for Chinese Health Care Market
Table 7.64: Pfizer Range of Endocrine Products for Chinese Health Care Market
Table 7.65: Pfizer Range of Women’s Health Products for Chinese Health Care Market
Table 7.66: Pfizer Range of Cardiovascular Disease Products for Chinese Health Care Market
Table 7.67: Pfizer China – Range of Oncology Products for Chinese Health Care Market
Table 7.68: Pfizer Key Consumer Healthcare Global Products
Table 7.69: Pfizer Key Speciality Care Global Products
Table 7.70: Pfizer Key Oncology Global Products
Table 7.71: Pfizer Key Global Established Products
Table 7.72: Pfizer Key Innovative Products in Emerging Markets
Table 7.73: Pfizer Key Animal Health Global Products
Table 7.74: Pfizer Product Sales with Significant Impact on Revenues 2013:2014 Comparison
Table 7.75: Roche Pharmaceuticals Product List in China
Table 7.76: Roche Global Sales (CHF Millions) by Therapeutic Area, 2012-2014 and Percentage Change (CER)
Table 7.77: Roche Pharmaceutical Division Sales from Brazil, China, India, Mexico, Russia, South Korea, Turkey, 2011-2014 and Percentage Change (CER)
Table 7.78: Seven Growth Platforms of Sanofi China
Table 7.79: Key Therapeutic Areas of Sanofi China
Table 8.1: Important Milestones in Amoytop Biotech’s Development
Table 8.2: Amoytop Biotech Main Objectives of Research and Development Division
Table 8.3: Amoytop Biotech Panel of Recombinant Protein Therapeutics in Clinical Studies
Table 8.4: Amoytop Biotech Portfolio of Patented Y-Shaped Branched Pegylated Recombinant Protein Therapeutics within Clinical Investigation in China
Table 8.5: Current Recombinant protein therapeutics by Amoytop Biotech
Table 8.6: Active Pharmaceutical Product Portfolio of Amoytop Biotech
Table 8.7: Milestones Achieved by FusoGen Pharmaceuticals
Table 8.8: Research and Development Sub-groups of FusoGen Pharmaceuticals
Table 8.9: Shanghai Huaguan Biochip Rapid Test Portfolio
Table 8.10: Shanghai Huaguan Biochip Multi Drugs of Abuse Test Profile
Table 8.11: Shanghai Huaguan Biochip Infectious Disease Test Portfolio
Table 8.12: Shanghai Huaguan Biochip Diagnostic Test Portfolio
Table 8.13: Shanghai Huaguan Biochip Laboratory Service Portfolio
Table 8.14: Intracellular Functions of the Gene Therapy Agent, Gendicine by SiBiono GeneTech
Table 8.15: Gendicine - Potential Oncology Indications for Future Approval
Table 8.16: Current Human Vaccine Portfolio of Sinovac Biotech
Table 8.17: Important Milestones in the History of Sinovac Biotech
Table 8.18: Pipeline Portfolio of Sinovac Biotech
Table 8.19: Total Sales Figures Sinovac Biotech 2007-2012
Table 9.1: Key Drivers of the Pharmaceutical Market in China
Table 9.2: Key Restraints of the Pharmaceutical Market in China
Table 9.3: Key Challenges of the Pharmaceutical Market in China
Table 9.4: Patent Expirations of Selected Top Brand Name Therapeutics by 2020
Table 9.5: Leading Pharmaceutical Areas with Significant Opportunities in China
LIST OF FIGURES
Figure 2.1: Proportional (%) Mortality Rate of Total Deaths in China, All Ages
Figure 3.1: China GDP Figures 2006-2015
Figure 3.2: Annual Health Expenditure in China 2006-2015
Figure 3.3: Global, Emerging Market & Developing Countries Economic Growth Change 2010-2013
Figure 3.4: Global, Emerging Market & Developing Countries & China Economic Growth Change 2010-2013
Figure 3.5: Global, Emerging Market & Developing Countries & Russia Economic Growth Change 2010-2013
Figure 3.6: Global, Emerging Market and Developing Countries and India Economic Growth Change 2010-2013
Figure 3.7: Global, Emerging Market and Developing Countries and Brazil Economic Growth Change 2010-2013
Figure 3.8: Global, US and Germany Economic Growth 2010-2013
Figure 3.9: US and UK Gross Domestic Product per capita Forecast 2010-2017
Figure 3.10: Global, France and Italy Economic Growth 2010-2013
Figure 3.11: France, Germay and Italy Gross Domestic Product per capita Forecast 2010-2017
Figure 3.12: Global, UK and Spain Economic Growth 2010-2013
Figure 3.13: Global, Japan and Canada Economic Growth 2010-2013
Figure 3.14: China, Brazil and India Gross Domestic Product per capita Forecast 2010-2017
Figure 4.1: The Chinese Healthcare Industry by Sector
Figure 4.2: Global Diabetes Market, USA, Europe, Japan, RoW, 2015
Figure 4.3: Diabetes Market China 2009-2015
Figure 4.4: Global Dementia Market 2011-2017
Figure 4.5: Market Share of State-Owned, Privately-Owned and Foreign-Owned Enterprises in the Chinese Vaccine Market
Figure 5.1: Projected Figures of Strategic Emerging Industry GDP Percentage Contribution to 2020
Figure 5.2: State Drug and Food Administration, China, Application and Approval Procedure for Imported Drugs
Figure 5.3: State Drug and Food Administration, China, Application and Approval Procedure for Clinical Trials
Figure 5.4: Revenue Share (Percentage) of Major Players in Chinese Pharmaceutical Distribution Market
Figure 5.5: Revenue Share (Billion $) of Major Players in Chinese Pharmaceutical Distribution Market
Figure 5.6: Number of Drugs on Essential Drug List by Western Therapeutic and Traditional Chinese Medicine, 2009-2014
Figure 5.7: Sales of Merck’s Zocor and its Performance After Inclusion on Essential Drug List
Figure 6.1: Three Tier ‘Pharmerging’ Markets with Potential for Significant Growth
Figure 6.2: Number of Investigational New Drug Applications in China 2003-2013
Figure 6.3: Number of New Drug Applications in China 2003-2013
Figure 6.4: Current Number of Novel Therapeutics in Phase I, Phase II and Phase III Clinical Trials in China
Figure 6.5: Percentage of Clinical Trial Drug by Disease State
Figure 6.6: China’s Regional Pharmaceutical Processing Trade Export Market Share Percentage
Figure 6.7: Contract Amount of China’s Regional Pharmaceutical Processing Trade Export
Figure 6.8: Top Five Contract Pharmaceutical Export Markets of China
Figure 7.1: Abbott Division Sales Percentage by Diagnostics, Nutrition, Medical Devices & Established Pharmaceuticals 2014
Figure 7.2: Abbott Medical Device Segment Sales 2014 – Vascular, Diabetes and Vision
Figure 7.3: Abbott Laboratories Geographic Distribution of Revenue –USA, Established and Emerging Markets
Figure 7.4: Abbott Laboratories Established and Emerging Revenue Share (%) 2012-2015
Figure 7.5: Abbott – Business Specialization Strategy: Diversified Medical Products and Research-Based Pharmaceuticals
Figure 7.6: Abbott Diversified Medical Product Portfolio
Figure 7.7: AbbVie Global Revenue 2013-2014
Figure 7.8: AbbVie Global, International and USA Total Revenue 2014
Figure 7.9: AbbVie Global, USA & International Revenue Generated 2013-2014
Figure 7.10: AbbVie Revenue Generated by Creon, DuoDopa and Synthroid 2013-2014
Figure 7.11: AstraZeneca Sales Revenue (US$ Millions) in China, FY2010-2014
Figure 7.12: AstraZeneca Global Revenue (Billions) by Geographic Area: USA, Europe, China, Japan, Canada, FY2014
Figure 7.13: AstraZeneca Cardiovascular Product (Atacand, Crestor, Seloken/Toprol-XL) Global Sales FY2010-2014
Figure 7.14: AstraZeneca Gastrointestinal Product (Nexium) Global Sales FY2010-2014
Figure 7.15: AstraZeneca Infection Product (Synagis) Global Sales FY2010-2014
Figure 7.16: AstraZeneca Neuroscience Product (Seroquel-IR, Seroquel-XR) Global Sales FY2010-2014
Figure 7.17: AstraZeneca Oncology Product (Zoladex) Global Sales FY2010-2014
Figure 7.18: AstraZeneca Respiratory/Inflammation Product (Pulmicort, Symbicort) Global Sales 2010-2012
Figure 7.19: Bayer Geographical Sales China, USA, Germany FY2013-2014
Figure 7.20: Bayer Sales Distribution by Division: Healthcare, Crop Science, Material Science FY2014
Figure 7.21: Bayer Healthcare Sales Breakdown: Pharmaceuticals and Consumer Health FY2014
Figure 7.22: Boehringer Ingelheim Global Sales by Geographic Region, Europe, Americas, Asia, Australia, Africa FY2014
Figure 7.23: Boehringer Ingelheim Sales by Product Class FY2014
Figure 7.24: Boehringer Ingelheim Oncology Compounds in Development
Figure 7.25: Lilly Global Revenue FY2010-FY2014
Figure 7.26: GlaxoSmithKline Total Sales, Pharmaceutical, Vaccine and Consumer Healthcare Sales 2012-2014 (? Billions)
Figure 7.27: GlaxoSmithKline Global Pharmaceutical Sales (? Millions) by Therapeutic Area, FY2012-2013
Figure 7.28: GlaxoSmithKline Sales by Therapeutic Area FY2014
Figure 7.29: GlaxoSmithKline Global Vaccine Sales, FY2012-2014
Figure 7.30: GlaxoSmithKline Global Sales by Geographic Region – USA, Europe, Emerging Markets, Japan, FY2012-2014
Figure 7.31: Johnson & Johnson Pharmaceutical Segment Sales (US$ Billion) by Therapeutic Area, 2012-2014
Figure 7.32: Novartis International Sales (%) by Geographic Region, FY2013-FY2014
Figure 7.33: Novartis International Sales (US$ Millions) by Geographic Region, FY2012-FY2014
Figure 7.34: Novo Nordisk Total China Sales FY2009-FY2014
Figure 7.35: Novo Nordsk Total Diabetes Care Market Sales Performance (DKK Millions) China FY2010-FY2014
Figure 7.36: Novo Nordisk Diabetes Care (NovoRapid/NovoLog, NovoMix/NovoLog Mix, Levemir, Modern Insulin, Human Insulin, Victoza) Sales Performance (DKK Millions) China FY2010-FY2014
Figure 7.37: Business Sectors – Pfizer China
Figure 7.38: Roche Total Global Sales (CHF Millions) FY2012-FY2014
Figure 7.39: Roche Global Sales (CHF Billions) by Therapeutic Area, FY2012-FY2014
Figure 7.40: Roche Pharmaceutical Division Emerging Market Total Sales FY2011-FY2014
Figure 7.41: Roche Pharmaceutical Division Sales from Brazil, China, India, Mexico, Russia, South Korea, Turkey, FY2012 - FY2014
Figure 7.42: Roche Pharmaceutical Division Sales in China FY2012-FY2014
Figure 7.43: Sanofi Geographic Market Share – Emerging Markets, USA and Western Europe FY2013-FY2014
Figure 7.44: Sanofi Geographic Market Share (%) –China, Russia and USA 2012
Figure 7.45: Sanofi Global Diabetes Revenue by Brand FY2014
Figure 7.46: Sanofi Global Rare Disease Revenue by Brand FY2014
Figure 7.47: Sanofi Global Multiple Sclerosis Revenue by Brand FY2014
Figure 7.48: Sanofi Global Oncology Revenue by Brand FY2014
Figure 8.1: FusoGen Pharmaceuticals Product Pipeline and Clinical Trial Progression
Figure 8.2: Shanghai Huaguan Biochip Serial Analysis of Gene Expression (SAGE) Service
Figure 8.3: Total Sales Figures Sinovac Biotech 2007-2012
Figure 8.4: Percentage of Sales Attributed to Healive Vaccine, 2009-2012
Figure 8.5: Reported Sales of Healive Vaccine, 2009-2012
Figure 8.6: Reported Sales of Bilive Vaccine, 2009-2012
Figure 8.7: Reported Sales of Anflu Vaccine, 2009-2012
Figure 8.8: Reported Sales of Panflu Vaccine, 2009-2011
Figure 2.1: Proportional (%) Mortality Rate of Total Deaths in China, All Ages
Figure 3.1: China GDP Figures 2006-2015
Figure 3.2: Annual Health Expenditure in China 2006-2015
Figure 3.3: Global, Emerging Market & Developing Countries Economic Growth Change 2010-2013
Figure 3.4: Global, Emerging Market & Developing Countries & China Economic Growth Change 2010-2013
Figure 3.5: Global, Emerging Market & Developing Countries & Russia Economic Growth Change 2010-2013
Figure 3.6: Global, Emerging Market and Developing Countries and India Economic Growth Change 2010-2013
Figure 3.7: Global, Emerging Market and Developing Countries and Brazil Economic Growth Change 2010-2013
Figure 3.8: Global, US and Germany Economic Growth 2010-2013
Figure 3.9: US and UK Gross Domestic Product per capita Forecast 2010-2017
Figure 3.10: Global, France and Italy Economic Growth 2010-2013
Figure 3.11: France, Germay and Italy Gross Domestic Product per capita Forecast 2010-2017
Figure 3.12: Global, UK and Spain Economic Growth 2010-2013
Figure 3.13: Global, Japan and Canada Economic Growth 2010-2013
Figure 3.14: China, Brazil and India Gross Domestic Product per capita Forecast 2010-2017
Figure 4.1: The Chinese Healthcare Industry by Sector
Figure 4.2: Global Diabetes Market, USA, Europe, Japan, RoW, 2015
Figure 4.3: Diabetes Market China 2009-2015
Figure 4.4: Global Dementia Market 2011-2017
Figure 4.5: Market Share of State-Owned, Privately-Owned and Foreign-Owned Enterprises in the Chinese Vaccine Market
Figure 5.1: Projected Figures of Strategic Emerging Industry GDP Percentage Contribution to 2020
Figure 5.2: State Drug and Food Administration, China, Application and Approval Procedure for Imported Drugs
Figure 5.3: State Drug and Food Administration, China, Application and Approval Procedure for Clinical Trials
Figure 5.4: Revenue Share (Percentage) of Major Players in Chinese Pharmaceutical Distribution Market
Figure 5.5: Revenue Share (Billion $) of Major Players in Chinese Pharmaceutical Distribution Market
Figure 5.6: Number of Drugs on Essential Drug List by Western Therapeutic and Traditional Chinese Medicine, 2009-2014
Figure 5.7: Sales of Merck’s Zocor and its Performance After Inclusion on Essential Drug List
Figure 6.1: Three Tier ‘Pharmerging’ Markets with Potential for Significant Growth
Figure 6.2: Number of Investigational New Drug Applications in China 2003-2013
Figure 6.3: Number of New Drug Applications in China 2003-2013
Figure 6.4: Current Number of Novel Therapeutics in Phase I, Phase II and Phase III Clinical Trials in China
Figure 6.5: Percentage of Clinical Trial Drug by Disease State
Figure 6.6: China’s Regional Pharmaceutical Processing Trade Export Market Share Percentage
Figure 6.7: Contract Amount of China’s Regional Pharmaceutical Processing Trade Export
Figure 6.8: Top Five Contract Pharmaceutical Export Markets of China
Figure 7.1: Abbott Division Sales Percentage by Diagnostics, Nutrition, Medical Devices & Established Pharmaceuticals 2014
Figure 7.2: Abbott Medical Device Segment Sales 2014 – Vascular, Diabetes and Vision
Figure 7.3: Abbott Laboratories Geographic Distribution of Revenue –USA, Established and Emerging Markets
Figure 7.4: Abbott Laboratories Established and Emerging Revenue Share (%) 2012-2015
Figure 7.5: Abbott – Business Specialization Strategy: Diversified Medical Products and Research-Based Pharmaceuticals
Figure 7.6: Abbott Diversified Medical Product Portfolio
Figure 7.7: AbbVie Global Revenue 2013-2014
Figure 7.8: AbbVie Global, International and USA Total Revenue 2014
Figure 7.9: AbbVie Global, USA & International Revenue Generated 2013-2014
Figure 7.10: AbbVie Revenue Generated by Creon, DuoDopa and Synthroid 2013-2014
Figure 7.11: AstraZeneca Sales Revenue (US$ Millions) in China, FY2010-2014
Figure 7.12: AstraZeneca Global Revenue (Billions) by Geographic Area: USA, Europe, China, Japan, Canada, FY2014
Figure 7.13: AstraZeneca Cardiovascular Product (Atacand, Crestor, Seloken/Toprol-XL) Global Sales FY2010-2014
Figure 7.14: AstraZeneca Gastrointestinal Product (Nexium) Global Sales FY2010-2014
Figure 7.15: AstraZeneca Infection Product (Synagis) Global Sales FY2010-2014
Figure 7.16: AstraZeneca Neuroscience Product (Seroquel-IR, Seroquel-XR) Global Sales FY2010-2014
Figure 7.17: AstraZeneca Oncology Product (Zoladex) Global Sales FY2010-2014
Figure 7.18: AstraZeneca Respiratory/Inflammation Product (Pulmicort, Symbicort) Global Sales 2010-2012
Figure 7.19: Bayer Geographical Sales China, USA, Germany FY2013-2014
Figure 7.20: Bayer Sales Distribution by Division: Healthcare, Crop Science, Material Science FY2014
Figure 7.21: Bayer Healthcare Sales Breakdown: Pharmaceuticals and Consumer Health FY2014
Figure 7.22: Boehringer Ingelheim Global Sales by Geographic Region, Europe, Americas, Asia, Australia, Africa FY2014
Figure 7.23: Boehringer Ingelheim Sales by Product Class FY2014
Figure 7.24: Boehringer Ingelheim Oncology Compounds in Development
Figure 7.25: Lilly Global Revenue FY2010-FY2014
Figure 7.26: GlaxoSmithKline Total Sales, Pharmaceutical, Vaccine and Consumer Healthcare Sales 2012-2014 (? Billions)
Figure 7.27: GlaxoSmithKline Global Pharmaceutical Sales (? Millions) by Therapeutic Area, FY2012-2013
Figure 7.28: GlaxoSmithKline Sales by Therapeutic Area FY2014
Figure 7.29: GlaxoSmithKline Global Vaccine Sales, FY2012-2014
Figure 7.30: GlaxoSmithKline Global Sales by Geographic Region – USA, Europe, Emerging Markets, Japan, FY2012-2014
Figure 7.31: Johnson & Johnson Pharmaceutical Segment Sales (US$ Billion) by Therapeutic Area, 2012-2014
Figure 7.32: Novartis International Sales (%) by Geographic Region, FY2013-FY2014
Figure 7.33: Novartis International Sales (US$ Millions) by Geographic Region, FY2012-FY2014
Figure 7.34: Novo Nordisk Total China Sales FY2009-FY2014
Figure 7.35: Novo Nordsk Total Diabetes Care Market Sales Performance (DKK Millions) China FY2010-FY2014
Figure 7.36: Novo Nordisk Diabetes Care (NovoRapid/NovoLog, NovoMix/NovoLog Mix, Levemir, Modern Insulin, Human Insulin, Victoza) Sales Performance (DKK Millions) China FY2010-FY2014
Figure 7.37: Business Sectors – Pfizer China
Figure 7.38: Roche Total Global Sales (CHF Millions) FY2012-FY2014
Figure 7.39: Roche Global Sales (CHF Billions) by Therapeutic Area, FY2012-FY2014
Figure 7.40: Roche Pharmaceutical Division Emerging Market Total Sales FY2011-FY2014
Figure 7.41: Roche Pharmaceutical Division Sales from Brazil, China, India, Mexico, Russia, South Korea, Turkey, FY2012 - FY2014
Figure 7.42: Roche Pharmaceutical Division Sales in China FY2012-FY2014
Figure 7.43: Sanofi Geographic Market Share – Emerging Markets, USA and Western Europe FY2013-FY2014
Figure 7.44: Sanofi Geographic Market Share (%) –China, Russia and USA 2012
Figure 7.45: Sanofi Global Diabetes Revenue by Brand FY2014
Figure 7.46: Sanofi Global Rare Disease Revenue by Brand FY2014
Figure 7.47: Sanofi Global Multiple Sclerosis Revenue by Brand FY2014
Figure 7.48: Sanofi Global Oncology Revenue by Brand FY2014
Figure 8.1: FusoGen Pharmaceuticals Product Pipeline and Clinical Trial Progression
Figure 8.2: Shanghai Huaguan Biochip Serial Analysis of Gene Expression (SAGE) Service
Figure 8.3: Total Sales Figures Sinovac Biotech 2007-2012
Figure 8.4: Percentage of Sales Attributed to Healive Vaccine, 2009-2012
Figure 8.5: Reported Sales of Healive Vaccine, 2009-2012
Figure 8.6: Reported Sales of Bilive Vaccine, 2009-2012
Figure 8.7: Reported Sales of Anflu Vaccine, 2009-2012
Figure 8.8: Reported Sales of Panflu Vaccine, 2009-2011
